Abstract
Kidney disease is a frequent complication of the course of heart transplantation. Acute and chronic renal failure increase the complexity of patient management and significantly contribute to early and late post-transplant morbidity and mortality. This chapter treats the risk factors, the clinical and pathogenetic mechanisms, and main histopathologic findings of acute and chronic renal diseases in heart-transplanted patients. Specific focus is given to acute and chronic calcineurin inhibitor renal toxicity. Current treatments for chronic kidney disease in such patients are also described.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Alvarez Arroyo MV, Suzuki Y, Yague A, et al. Role of endogenous vascular endothelial growth factor in tubular cellular protection against acute cyclosporine toxicity. Transplantation. 2002;74:1618–24.
Andreassen AK, Andersson B, Gustafsson F, Eiskjaer H, Rådegran G, Gude E, Jansson K, Solbu D, Karason K, Arora S, Dellgren G, Gullestad L. Everolimus initiation with early calcineurin inhibitor withdrawal in de novo heart transplant recipients: three-year results from the randomized SCHEDULE study. Am J Transplant. 2016;16:1238–47. doi:10.1111/ajt.13588.
Bloom RD, Doyle AM. Kidney disease after heart and lung transplantation. Am J Transplant. 2006;6:671–9.
Cornu C, Dufays C, Gaillard S, Gueyffier F, Redonnet M, Sebbag L, Roussoulières A, Gleissner CA, Groetzner J, Lehmkuhl HB, Potena L, Gullestad L, Cantarovich M, Boissonnat P. Impact of the reduction of calcineurin inhibitors on renal function in heart transplant patients: a systematic review and meta-analysis. Br J Clin Pharmacol. 2014;78:24–32.
Costanzo MR, Dipchand A, Starling R, et al. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. J Heart Lung Transplant. 2010;29:914–56.
Gonzales-Vilchez F, Vazquez de Prada JA. Chronic renal insufficiency in heart transplant recipients: risk factors and management options. Drugs. 2014;74:1481–94.
Gullestad L, Mortensen SA, Eiskjær H, Riise GC, Mared L, Bjørtuft O, Ekmehag B, Jansson K, Simonsen S, Gude E, Rundqvist B, Fagertun HE, Solbu D, Iversen M. Two-year outcomes in thoracic transplant recipients after conversion to everolimus with reduced calcineurin inhibitor within a multicenter, open-label, randomized trial. Transplantation. 2010;90:1581–9.
Hillege HL, Nitsch D, Pfeffer MA, et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation. 2006;113:671–8.
Ishani A, Erturk S, Hertz M, et al. Predictors of renal function following lung or heart-lung transplantation. Kidney Int. 2002;61:2228–34.
Kahan B, Ponticelli C. Immunosuppressive drugs: molecular and cellular mechanisms of action. London: Martin Dunitz; 2000. p. 314–47.
KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3(1). http://www.kidney-international.org.
Kriz W, Kaissling B, Le Hir M. Epithelial-mesenchymal transition (EMT) in kidney fibrosis: fact or fantasy? J Clin Invest. 2011;121:468–74.
Mihatsch MJ, Thiel G, Basler V, et al. Morphological patterns in cyclosporine-treated renal transplant recipients. Transplant Proc. 1985;17 Suppl 1:101–16.
Myers BD, Ross J, Newton L, Luetscher J, Perlroth M. Cyclosporine-associated chronic nephropathy. N Engl J Med. 1984;311(11):699–705.
Nizze H, Mihatsch MJ, Zollinger HU, Brocheriou C, Gokel JM, Henry K, Sloane JP, Stovin PG. Cyclosporine-associated nephropathy in patients with heart and bone marrow transplants. Clin Nephrol. 1988;30(5):248–60.
Olyaei AJ, De Mattos A, Bennett WM. Nephrotoxicity of immunosuppressive drugs: new insight and preventive strategies. Curr Opin Crit Care. 2001;7:384–9.
Potena L, Prestinenzi P, Bianchi IG, Masetti M, Romani P, Magnani G, Fallani F, Coccolo F, Russo A, Ponticelli C, Rapezzi C, Grigioni F, Branzi A. Cyclosporine lowering with everolimus versus mycophenolate mofetil in heart transplant recipients: long-term follow-up of the SHIRAKISS randomized, prospective study. J Heart Lung Transplant. 2012;31:565–70.
Singh M, Shullo M, Kormos RL, et al. Impact of renal function before mechanical circulatory support on post-transplant renal outcomes. Ann Thorac Surg. 2001;91:1348–54.
Yango A, Morrisey P, Monaco A, et al. Successful treatment of tacrolimus-associates thrombotic microangiopathy with sirolimus conversion and plasma axchange. Clin Nephrol. 2002;5:77–8.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Magnani, G., Valente, M., Marchini, F. (2016). Chronic Kidney Disease After Heart Transplantation: Risk Factors, Clinics, and Histopathology. In: Leone, O., Angelini, A., Bruneval, P., Potena, L. (eds) The Pathology of Cardiac Transplantation. Springer, Cham. https://doi.org/10.1007/978-3-319-46386-5_21
Download citation
DOI: https://doi.org/10.1007/978-3-319-46386-5_21
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-46384-1
Online ISBN: 978-3-319-46386-5
eBook Packages: MedicineMedicine (R0)